Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | KYAT1 | Q16773 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740055 | 1.00 | MAPT (0.50) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL20142641 | 0.88 | KYAT1 (0.60) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL20142642 | 0.88 | KYAT1 (0.60) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL20159628 | 0.88 | KYAT1 (0.60) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL18177677 | 0.85 | MAPT (0.52) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL12266608 | 0.85 | MEN1 (0.64) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL6303636 | 0.85 | KYAT1 (0.62) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL18900229 | 0.85 | KYAT1 (0.62) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL27841712 | 0.85 | MEN1 (0.64) | MAPTNPSR1ATMKYAT1GAA | |
| SCHEMBL11753054 | 0.84 | GAA (0.63) | MAPTNPSR1ATMKYAT1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043995-A1 | Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them | BIGNON ERIC (FR) | 2004-03-04 | — | — | US | disclosed |
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043995-A1 | Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them | CCKAR, CCKBR, NPY1R | MAPT 4432/4885NPSR1 268/4885ATM 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.